The 17th Annual Pain Therapeutics Summit
The Annual Pain Therapeutics Summit has the objective to identify and advance novel pain drugs through preclinical, clinical development and commercialization. It brings leaders together from the fields of advanced medicine and science, academia and government. This year s event will highlight novel therapeutics in the field of pain and novel trends in pain management, as well as panel discussions on key issues facing pain research today. The event is a prominent gathering of experts dedicated to improving the lives of those suffering from chronic pain. Please find more information here.
About
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as may, intends, can, might, will, expect, plan, possible, believe and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from its fundraising and Ensysce s and its partners ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the
Contact:
Tel: (858) 263-4196
(C) 2023 Electronic News Publishing, source